Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ATXS 
Astria Therapeutics Inc (ATXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: ATXS (2-star) is a SELL. SELL since 4 days. Simulated Profits (47.22%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13
1 Year Target Price $13
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 718.13M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 9 | Beta 0.02 | 52 Weeks Range 3.56 - 5784.30 | Updated Date 02/27/2026 |
52 Weeks Range 3.56 - 5784.30 | Updated Date 02/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Earnings Date
Report Date 2026-03-05 | When - | Estimate -0.545 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4830.6% |
Management Effectiveness
Return on Assets (TTM) -26.94% | Return on Equity (TTM) -43.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 590189262 | Price to Sales(TTM) 1017.18 |
Enterprise Value 590189262 | Price to Sales(TTM) 1017.18 | ||
Enterprise Value to Revenue 835.96 | Enterprise Value to EBITDA -7.57 | Shares Outstanding 57084838 | Shares Floating 39176183 |
Shares Outstanding 57084838 | Shares Floating 39176183 | ||
Percent Insiders 0.48 | Percent Institutions 94.9 |
About Astria Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-06-25 | Co-Founder, CEO, President & Director Ms. Jill C. Milne Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.astriatx.com |
Full time employees 78 | Website https://www.astriatx.com | ||
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.